BOULDER - ArrayBiopharma Inc. (Nasdaq: ARRY) in Boulder will report financial results for the third quarter of its 2014 fiscal year and hold a conference call to discuss those results on Tuesday, April 29.

Chief executive Ron Squarer and chief financial officer Michael Carruthers will lead the call that begins at 7 a.m. Mountain time.

To listen in, call 1-800-708-4540 toll-free, of 1-847-619-6397 for a toll. Pass code is 36946658.  A webcast, including replay and conference call slides can be accessed on line here.

Also, following the recent announcement by Novartis and GlaxoSmithKline that they have entered into a definitive agreement to exchange certain assets, Array reports that Novartis has indicated that it will continue to honor its obligations under the Array-Novartis agreement relating to binimetinib (MEK162), including obligations to support ongoing clinical trials.

In April 2010, Array entered into an agreement under which Novartis received exclusive worldwide rights to binimetinib. If Novartis' binimetinib development and commercialization rights are returned to Array, Novartis is required to provide support for ongoing clinical studies as specified in that agreement.